Mylan pursuit hasn't stopped Perrigo from scouting its own deals: CEO

Perrigo may be embroiled in a takeover fight with pursuer Mylan, but that hasn't stopped it from pursuing tie-ups of its own--even $1 billion-plus buys.

White House urged to stop states' 'rationing' of hep C drugs

Hep C drugs like Gilead Sciences' Sovaldi and AbbVie's Viekira Pak can cure hepatitis C, preventing people from getting liver disease. But in some states like Illinois, a person on Medicaid can't get Sovaldi unless they already have advanced liver disease. Even then, other restrictions can block them from access to the pricey meds. This kind of rationing is to save money, not lives, and is discriminatory White House medical advisors have told the administration. Experts have urged a reluctant administration to lay down some consistent guidelines for Medicaid on use of the new drugs.

U.S. patent office puts new Copaxone's IP shield under the lens

Teva's patents on Copaxone faced plenty of scrutiny before they were eventually upturned, paving the way for Sandoz's generic, Glatopa. Now, though, its IP protection on its new, long-acting version of the drug is under the microscope, too--and the Israeli drugmaker's prospects for hanging onto its patents don't look great.

Eli Lilly pops the bubbly on U.S. Alimta patent victory

Eli Lilly has fought tooth and nail to protect a patent for its blockbuster cancer drug Alimta, chalking up some victories in the U.S. despite setbacks overseas. Now the company is celebrating a big win as a federal court ruled in its favor, barring copycat versions of the drug and granting Lilly 5 more years of U.S. exclusivity for Alimta.

Teva bows out of voting on Mylan's proposed deal for Perrigo

Friday, Mylan's shareholders will vote on whether the company should move ahead with its hostile bid for Perrigo. But Teva won't be among them, despite the fact that it built up a 4.61% Mylan stake when it was trying to buy the company earlier this year.

Stock slide makes biopharma deals more enticing for Gilead (and everyone else)

Analysts and investors may have been ready for Gilead Sciences to make an M&A move before now. But with stocks on a slide, they might be glad Gilead hasn't yet.

Who should Allergan buy next? We asked, you answered

Serial buyer Allergan is getting ready to head back to the bargaining table, and there's plenty of buzz about who its next target will be. Who should it be, though, as far as FiercePharma readers are concerned? That's the question we posed last Tuesday, and since then, more than 500 of you have weighed in. 

UPDATED: With vote approaching, Perrigo chief slams Mylan's 'troubling' values

There are just three days left until Mylan's shareholders decide whether the company should push forward with its hostile pursuit of Perrigo. And just in case they do, Perrigo is making sure its own shareholders are ready to shoot it down.

Shire rejigs manufacturing deal to step up Cinryze production

Shire has big plans for rare-disease drug Cinryze, which it acquired through its ViroPharma buyout. And it's struck a new deal to make sure it has the capacity to realize them.

Bass failed at challenging Acorda's patents. Can pharma rest easy now?

On his first trip up to the patent-office plate, Kyle Bass struck out. A U.S. review board nixed the hedge funder's challenge to two Acorda Therapeutics patents, sending the drugmaker's shares soaring--and showing Bass that his short-selling crusade against "low quality" pharma patents won't be an easy home run.

Bristol-Myers, Sanofi catch a break in Plavix marketing case

Bristol-Myers Squibb and Sanofi scored a victory in a False Claims Act marketing case over its blood-thinner, Plavix, as a federal judge in New Jersey tossed out some allegations from a former Sanofi sales rep that the company made misleading statements about the med to gain more Medicare and Medicare coverage.

Allergan recalls eye drugs after patients complain of particles, blurred vision

Since Allergan and Actavis joined hands to become a new-look Allergan, the company has already had to recall a from the Actavis side. Now, it's recalling one from the Allergan side, putting a call out for certain lots of eye-treatment ointments sold in the U.S.--and it's already received some consumer complaints.

J&J uses share-the-wisdom approach to spread the word on Prezcobix

Johnson & Johnson is trying a new tack on the old "Talk to your doctor" advice. With a new campaign for its HIV drug Prezcobix, the company is urging potential patients to snap a photo and send it to their physicians to see if the drug is right for them.

Pharma junkets for U.K. docs trigger tough new Sunshine rules, penalties

England may have been behind the U.S. in shining the light on financial ties between pharma and physicians, but that's changing. Not only will National Health Service doctors be required to declare all gifts they receive from drugmakers. They'll also face losing their jobs--or even jail--if pharma payments influence their work.

Analysts: Gilead's hep C scripts keep slowing, and Q3 sales forecasts should too

Last quarter, Gilead reported a slowdown for its quick-launching hep C treatments--and that's a trend that's still ongoing, according to a pair of RBC Capital Markets analysts.

Takeda takes unexpected blow as blockbuster Velcade patent ruled invalid

With approvals in the U.S and Europe expected soon, it looked like Takeda would have time to get its new multiple myeloma treatment into the market before patents fell off of blockbuster Velcade in 2022. But CEO Christophe Weber may need to plot a new strategy after a federal judge overturned a key patent, putting the Japanese drugmaker's drug vulnerable to generics 5 years early.

Powerful cancer alliance joins cost-effectiveness drug crusade

The American Society of Clinical Oncology unveiled its framework for assessing cancer drugs earlier this summer, breaking new ground in helping doctors size up competing treatments. Now, the National Comprehensive Cancer Network is going a few steps farther.

Ackman's Valeant ties pay off yet again with Sprout buy

Bill Ackman's relationship with Valeant has paid off big-time since the hedge fund manager first teamed up with the Canadian pharma on its hostile pursuit of Allergan. And this time, it's an investment in Sprout Pharmaceuticals--Valeant's latest pickup--that's bringing in the bucks.

Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects of China's stock market meltdown and saw values rise 23%. But, of course, averages come from the highs and the lows and some players have actually seen share price declines during this bull market.

Novartis shells out up to $1B to test GSK's Arzerra in MS

Thanks to the companies' recent multi-billion-dollar asset swap, Novartis already has the rights to former GlaxoSmithKline drug ofatumumab's cancer applications. But now, it's forking over up to $1 billion to gain full control of the med--currently marketed as Arzerra--and to test it as a therapy for multiple sclerosis.